Due to the increase of antifungal drug resistance and difficulties associated with drug administration, new antifungal agents for invasive fungal infections are needed. SCY-247 is a second-generation fungerp antifungal compound that interferes with the synthesis of the fungal cell wall polymer β-(1,3)-d-glucan. We conducted an extensive antifungal screen of SCY-247 against yeast and mold strains compared with the parent compound ibrexafungerp (IBX; formerly SCY-078) to evaluate the in vitro antifungal properties of SCY-247. SCY-247 demonstrated similar activity to IBX against all of the organisms tested. Moreover, SCY-247 showed a higher percentage of fungicidal activity against the panel of yeast and mold isolates than IBX. Notably, SCY-247 showed considerable antifungal properties against numerous strains of Candida auris. Additionally, SCY-247 retained its antifungal activity when evaluated in the presence of synthetic urine, indicating that SCY-247 maintains activity and structural stability under environments with decreased pH levels. Finally, a time-kill study showed SCY-247 has potent anti-Candida, -Aspergillus, and -Scedosporium activity. In summary, SCY-247 has potent antifungal activity against various fungal species, indicating that further studies on this fungerp analog are warranted.

中文翻译：

---

第二代 Fungerp 类似物 SCY-247 显示出对念珠菌和其他临床相关真菌分离株的有效体外活性

由于抗真菌药物耐药性的增加以及与给药相关的困难，需要用于侵袭性真菌感染的新型抗真菌药物。SCY-247是一个第二代fungerp抗真菌化合物与真菌细胞壁聚合物β-（1,3）的合成干涉- d -葡聚糖。与母体化合物 ibrexafungerp（IBX；以前的 SCY-078）相比，我们对 SCY-247 对酵母和霉菌菌株进行了广泛的抗真菌筛选，以评估体外SCY-247 的抗真菌特性。SCY-247 表现出与 IBX 相似的针对所有测试生物的活性。此外，与 IBX 相比，SCY-247 对酵母和霉菌分离物组显示出更高百分比的杀真菌活性。值得注意的是，SCY-247 对多种耳念珠菌菌株显示出相当大的抗真菌特性。此外，当在合成尿存在下进行评估时，SCY-247 保留了其抗真菌活性，表明 SCY-247 在 pH 值降低的环境下保持活性和结构稳定性。最后，一项时间杀死研究表明 SCY-247 具有有效的抗念珠菌、 -曲霉和 -赛多孢菌活动。总之，SCY-247 对各种真菌物种具有强大的抗真菌活性，表明需要对这种真菌类似物进行进一步研究。